These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Combination therapy with HMG CoA reductase inhibitors and gemfibrozil: practical or perilous? Duell PB; Illingworth DR Heart Dis Stroke; 1993; 2(3):260-2. PubMed ID: 8137035 [No Abstract] [Full Text] [Related]
4. Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin. Kahri AJ; Valkonen MM; Vuoristo MK; Pentikäinen PJ Ann Pharmacother; 2004 Apr; 38(4):719. PubMed ID: 14966253 [No Abstract] [Full Text] [Related]
5. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. ter Avest E; Abbink EJ; de Graaf J; Tack CJ; Stalenhoef AF Eur J Clin Invest; 2005 Sep; 35(9):558-64. PubMed ID: 16128862 [TBL] [Abstract][Full Text] [Related]
6. Statins in heart failure - a failure? Reiner Z Nutr Metab Cardiovasc Dis; 2008 Jul; 18(6):397-401. PubMed ID: 18579352 [No Abstract] [Full Text] [Related]
7. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Tobert JA Nat Rev Drug Discov; 2003 Jul; 2(7):517-26. PubMed ID: 12815379 [TBL] [Abstract][Full Text] [Related]
8. Statins' role in prevention. Do statins have a role in primary prevention of cardiovascular events? Can Fam Physician; 2004 Aug; 50():1091. PubMed ID: 15455806 [No Abstract] [Full Text] [Related]
9. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment. Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315 [TBL] [Abstract][Full Text] [Related]
10. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835 [TBL] [Abstract][Full Text] [Related]
11. Low-risk older patients (50 years and older) with raised high-sensitivity CRP (hs-CRP) benefit from rosuvastatin therapy: the JUPITER study. Cardiovasc J Afr; 2008; 19(6):332-4, discussion 335. PubMed ID: 19104734 [No Abstract] [Full Text] [Related]
12. The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome. Prescott WA; Streetman DA; Streetman DS Ann Pharmacother; 2004 Dec; 38(12):2105-14. PubMed ID: 15507504 [TBL] [Abstract][Full Text] [Related]
13. [Hyperlipidemia: decreasing lipid values and effects of statins]. Mathes P Z Kardiol; 2002; 91 Suppl 2():25-9. PubMed ID: 12436762 [No Abstract] [Full Text] [Related]
14. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre. de Langen JJ; van Puijenbroek EP Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271 [TBL] [Abstract][Full Text] [Related]